reported a first‐in‐human Phase 1 study to establish the safety and tolerability of delivering single ascending doses of Cavrotolimod to 16 healthy participants, over four dose levels.[207] Rather than a classical gold‐cored SNA, Cavrotolimod is a liposome‐cored SNA with a shell of CpG oligonucleotides as TLR9 agonists for cancer immunotherapy. The gene discussed is TLR9; the disease is cancer.